News | January 11, 2016

AiCure’s Artificial Intelligence Platform Draws $12.25 Million Series A (New York, NY) – January 11, 2016 – AiCure, an artificial intelligence company connecting the world’s patients to better treatments and improved health, has closed a Series...

News | January 7, 2016

Principia Biopharm advances BTK inhibitor program in autoimmune disease and FGFR inhibitor program in oncology Initiates Phase 2 clinical trial of BTK inhibitor PRN1008 in orphan autoimmune disease Advances Phase 1 clinical trial of FGFR1-4 inhibitor PRN1371 in solid...

News | January 7, 2016

Dimension Therapeutics Announces Initiation of Phase 1/2 Study for DTX101 for the Treatment of Hemophilia B Receives Positive Opinion on European Orphan Drug Designation CAMBRIDGE, Mass., Jan. 07, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc....

News | January 6, 2016

Dimension Therapeutics Announces Orphan Drug Designation of DTX301 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a leading gene therapy company...

News | December 16, 2015

Versartis’ VRS-317 6-Month Data Published in The Journal of Clinical Endocrinology & Metabolism Results Show Positive Safety and Efficacy Data With Similar Outcomes Across Three Dosing Regimens MENLO PARK, Calif., Dec. 16, 2015 (GLOBE NEWSWIRE) —...
tempus libero. diam dolor. velit, Aenean Curabitur neque. sed